Canada Markets closed

BELLUS Health Inc. (BLU.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
10.30-0.10 (-0.96%)
At close: 04:00PM EDT

BELLUS Health Inc.

275 Armand-Frappier Boulevard
Laval, QC H7V 4A7

Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Mr. Roberto Francesco BelliniPres, CEO & Director353.03kN/A1980
Mr. Ramzi BenamarChief Financial Officer607.33kN/A1973
Dr. Denis GarceauChief Scientific Officer431.87kN/A1957
Mr. Tony MatzouranisSr. VP of Bus. Devel.272.89kN/A1973
Dr. Catherine M. Bonuccelli M.D.Chief Medical Officer703.77kN/A1958
Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBAChief Operating OfficerN/AN/A1959
Mr. Daniel MatthewsDirector of Investor Relations & CommunicationsN/AN/AN/A
Mr. Sebastien RoyCorp. Sec.N/AN/A1976
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Corporate Governance

BELLUS Health Inc.’s ISS Governance QualityScore as of February 1, 2023 is 9. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.